OverviewSuggest Edit

Aetion is a healthcare technology company that delivers the real-world analytics and evidence needed for value-based healthcare. With its patented rapid-cycle analytics technology, the platform utilizes the everyday clinical and financial interactions of the healthcare system to unlock essential evidence about the effectiveness and value of medical treatments. Founded by Harvard Medical School faculty members and top big data technologists, Aetion enables payers and providers to collaborate with biopharmaceutical and medical device companies in real-time to develop therapeutic insights and make smart choices in patient care.

TypePrivate
Founded2013
HQNew York, NY, US
Websiteaetion.com

Latest Updates

Employees (est.) (Apr 2021)182(+2%)
Cybersecurity ratingBMore

Key People/Management at Aetion

Carolyn Magill

Carolyn Magill

Chief Executive Officer and Director
Jeremy Rassen

Jeremy Rassen

Co-Founder, President, Chief Science Officer, and Board Director
Scott Gottlieb

Scott Gottlieb

Director
Lori Bennett

Lori Bennett

General Counsel
Liz Dematteis

Liz Dematteis

Chief Marketing Officer
John Turek

John Turek

Chief Technology Officer
Show more

Aetion Office Locations

Aetion has offices in New York, Boston, El Segundo and Bougival
New York, NY, US (HQ)
5 Pennsylvania Plaza 7th floor
Boston, MA, US
50 Congress St #1025
El Segundo, CA, US
840 Apollo St #100
Bougival, FR
40 Chemin de l'Ariel
Show all (4)

Aetion Financials and Metrics

Summary Metrics

Founding Date

2013

Aetion total Funding

$93.6 m

Aetion latest funding size

$19 m

Time since last funding

8 months ago

Aetion investors

Aetion's latest funding round in August 2020 was reported to be $19 m. In total, Aetion has raised $93.6 m
Show all financial metrics

Aetion Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Aetion Online and Social Media Presence

Embed Graph

Aetion News and Updates

Aetion cracks top 10 of Fast Company’s 100 Best Workplaces for Innovators

The healthcare company checks in at number 10. The healthcare technology company uses data and predictive modeling to answer questions about how certain treatments will affect different sectors of the population. The company has a separate labs team completely focused on innovation. The labs team, s…

FDA, Aetion team up to find answers around COVID-19 risk factors, treatments

By using real-world patient information, the agency hopes to research population health trends and medication efficacy.

Drug pricing review group signs deal with Aetion for patient data

The Institute for Clinical and Economic Review (ICER), a small but influential Boston-based research group, has signed a deal with private technology company Aetion to help it use patient health data in its reports on whether individual drugs are priced properly.

New Aetion Tool Brings Real-World Evidence Research to Small and Mid-Sized Pharma Companies

NEW YORK, Nov. 1, 2019 /PRNewswire/ -- Today Aetion, the health care technology company that delivers real-world evidence for life sciences companies, payers, and regulatory agencies, announced a new integrated solution focused on advancing the use of real-world evidence for small and...

Horizon Healthcare Services, Inc., Partners with Aetion to Improve Treatment Pathways Using Predictive Modeling and Machine Learning

NEW YORK, June 7, 2019 /PRNewswire/ -- Today Aetion announced a partnership with Horizon Healthcare Services, Inc. (Horizon), New Jersey's largest health insurer, to use medical and pharmacy claims data to optimize treatment pathways across nine therapeutic areas. The evidence they...

Health care startup Aetion raises $27 million for real-world evidence platform

Aetion, a New York health care startup that aims to bridge the gap among payers, providers, and pharmaceutical companies, has raised $27 million.
Show more

Aetion Blogs

Research spotlight: Using RWE to assess molecular insights, published in Science

Earlier this year, Aetion co-authored a study published in Science that demonstrates how real-world evidence (RWE) can inform drug development by taking lab-generated hypotheses and assessing them in real clinical practice.  The study, which was led by Nevan Krogan, Ph.D. of the Quantitative Bioscie…

Leveraging RWE in regulatory submissions of medical devices: Three takeaways for medical device and diagnostic companies

The U.S. Food and Drug Administration’s (FDA’s) Center for Devices and Radiological Health (CDRH) recently released a position statement on the use of real-world evidence (RWE) in regulatory decision-making for medical devices, as well as 90 examples of RWE supporting FDA approvals. This data both c…

Research spotlight: Using RWD to evaluate risk of COVID-19 reinfection

To date, approximately 66 million patients have recovered from COVID-19, globally. As the virus continues to be transmitted and patients with evidence of infection are re-exposed, there is a pressing need to understand the level of protection, if any, that is offered from humoral antibody response. …

Research spotlight: Understanding and correcting bias in RWE studies

Real-world evidence (RWE) studies are often criticized for their susceptibility to certain biases which—by design—don’t affect randomized controlled trials (RCTs). It’s important for RWE researchers to understand and correct these biases to continue to advance the field, and to reinforce the fact th…

How RWE can advance understanding of—and boost public confidence in—COVID-19 vaccine safety

After nearly one year of suffering, isolation, and economic downturn on an unprecedented international scale, the expedited development and authorization of COVID-19 vaccines has shown us the light at the tunnel’s end. Having an end in sight is not the same as getting there, however: inoculating the…

Opportunities to advance RWE in Europe: Assessing today’s landscape and priorities for future guidance

Real-world evidence (RWE) has emerged as an important tool for global regulators, health technology assessment (HTA) bodies, and biopharma organizations alike as they’ve sought innovative ways to inform and accelerate decision-making.  In Europe, standard-setting organizations like the European Medi…
Show more

Aetion Frequently Asked Questions

  • When was Aetion founded?

    Aetion was founded in 2013.

  • Who are Aetion key executives?

    Aetion's key executives are Carolyn Magill, Jeremy Rassen and Scott Gottlieb.

  • How many employees does Aetion have?

    Aetion has 182 employees.

  • Who are Aetion competitors?

    Competitors of Aetion include Rightway Healthcare, CellTrak and IDDI.

  • Where is Aetion headquarters?

    Aetion headquarters is located at 5 Pennsylvania Plaza 7th floor, New York.

  • Where are Aetion offices?

    Aetion has offices in New York, Boston, El Segundo and Bougival.

  • How many offices does Aetion have?

    Aetion has 4 offices.